<SEC-DOCUMENT>0001558370-17-006054.txt : 20170807
<SEC-HEADER>0001558370-17-006054.hdr.sgml : 20170807
<ACCEPTANCE-DATETIME>20170807080714
ACCESSION NUMBER:		0001558370-17-006054
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170807
DATE AS OF CHANGE:		20170807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemphire Therapeutics Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-217296
		FILM NUMBER:		171010112

	BUSINESS ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
		BUSINESS PHONE:		248-980-6538

	MAIL ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>f424b3.htm
<DESCRIPTION>424B3
<TEXT>
<!--HTML document created with Merrill Bridge  7.2.100.0-->
<!--Created on: 8/7/2017 6:05:44 AM-->
<html>
	<head>
		<title>
			gemp_Current_Folio_424B3
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:71.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:28.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:71.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:28.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Filed Pursuant to Rule 424(b)(3)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:71.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:28.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Registration No. 333-217296</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;Prospectus Supplement No. 5</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">(to Prospectus dated April 21, 2017)</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">2,317,460 Shares</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"><img src="f424b3g001.jpg" style="width: 2.364583in; height: 1.333333in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Common Stock</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus supplement supplements the prospectus dated April 21, 2017 (the &#x201C;Prospectus&#x201D;), which forms a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-217296). This prospectus supplement is being filed to update and supplement the information in the Prospectus with information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on August 7, 2017 (the &#x201C;Current Report&#x201D;). Accordingly, we incorporate by reference the Current Report into this prospectus supplement.&nbsp; </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The Prospectus and this prospectus supplement relate to the resale, from time to time, of up to 2,317,460 shares of common stock of Gemphire Therapeutics Inc. (the &#x201C;Company&#x201D;) by the selling stockholders listed on page 10 of the Prospectus, which includes (i) 1,324,256 shares of our common stock, par value $0.001 per share (the &#x201C;Common Stock&#x201D;) issued on March 15, 2017 and (ii) an aggregate of 993,204 shares of our Common Stock (the &#x201C;Warrant Shares&#x201D;) issuable upon exercise of common stock purchase warrants issued on March 15, 2017 (the &#x201C;Warrants&#x201D;) by the selling stockholders listed on page 10 of the Prospectus, including their transferees, pledgees or donees or their respective successors (the &#x201C;Selling Stockholders&#x201D;). </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">This prospectus supplement should be read in conjunction with the Prospectus. This prospectus supplement updates and supplements the information in the Prospectus. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">Our Common Stock trades on the NASDAQ Global Market under the symbol &#x201C;GEMP&#x201D;. On August 4, 2017, the last reported sale price per share of our Common Stock was $18.66 per share.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements for the Prospectus, this prospectus supplement and future filings.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Investing in our Common Stock involves a high degree of risk. See &#x201C;Risk Factors&#x201D; beginning on page&nbsp;6 of the Prospectus.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">The date of this prospectus supplement is August 7,&nbsp;2017.</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>f424b3g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 f424b3g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "  .,# 2(  A$! Q$!_\0
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
